MAPK3 and drug-induced dyskinesia: Levetiracetam had significant regulatory effects on ΔFosB, p-ERK1/2, and p-DARPP-32 expression, which correlated with reduction of abnormal involuntary movements (AIMs) demonstrating the specific effects of this antiepileptic drug on dyskinesia mechanisms.